- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01396369
Flaxseed Lignan (Brevail)
Impact of Flaxseed Lignan (Brevail) on Polycystic Ovarian Syndrome
PCOS is a disorder which is characterized by hyperandrogenism (high serum male hormone levels), ovulatory dysfunction, and polycystic ovaries (multiple follicles-over 12- in the ovary). There is no universally accepted definition for PCOS. The Rotterdam criteria require 2 of 3 criteria for diagnosis, including hyperandrogenism (clinical hirsutism or serum hormone measurement), oligomenorrhea/amenorrhea, and ultrasound findings of polycystic ovaries.
This study is a prospective randomized pilot study designed to evaluate the effects of flaxseed supplementation (with Brevail) on hormonal and lipid metabolism balance in polycystic ovarian syndrome (PCOS) patients.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- The University of Kansas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be 18 to 40 year old female with:
- Diagnosis of PCOS by menstrual irregularity (fewer than 9 menses annually/interval over 40 days), Ferriman-Galleway score >8, and/or hyperandrogenemia defined as total testosterone >80ng/dl or bioavailable testosterone >8.4 ng/dl.
- Mentally competent.
Exclusion Criteria:
- Use of oral contraceptives, spironolactone, or insulin-sensitizing agents within the past 2 months.
- Long-term or chronic use of oral antibiotics.
- Hysterectomy.
- FSH >15.
- Pregnancy/lactation.
- Consumption of flaxseed within the last month.
- Diagnosis of thyroid disease, nonclassical adrenal hyperplasia, and hyperprolactinemia.
- Use of any dietary fiber supplements which are newly started (within the past 6 months) and agreement not to use any new fiber supplements during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Birth control
|
In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests.
After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day).
The patients will return to the clinic for a follow up visit after 3 months.
If no side effects, Brevail and OC will be continued for 3 more months.
The control group will also have a follow up after 3 months of OC.
Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
|
EXPERIMENTAL: Birth control plus Brevail
|
In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests.
After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day).
The patients will return to the clinic for a follow up visit after 3 months.
If no side effects, Brevail and OC will be continued for 3 more months.
The control group will also have a follow up after 3 months of OC.
Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary outcomes to assess are the changes of testosterone levels and hirsutism.
Time Frame: up to 6 months
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary outcomes to assess are the lipid profile and estrogen levels.
Time Frame: Up to 6 months
|
Up to 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sam Kim, MD, The University of Kansas Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12459
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovarian Syndrome
-
Northwell HealthWithdrawnPolycystic Ovarian Syndrome (PCOS) | Patients Sensitive to Exogenous Gonadotropins | Ovarian Hyper Stimulation Syndrome (OHSS)United States
-
Etlik Zubeyde Hanim Womens' Health and Teaching...CompletedOvarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome
-
Bruce LesseyTerminatedPolycystic Ovarian SyndromeUnited States
-
Kufa UniversityCompletedPolycystic Ovary SyndromeIraq
-
Duke UniversityTerminatedPolycystic Ovarian SyndromeUnited States
-
V.K.V. American Hospital, IstanbulUnknownPolycystic Ovarian SyndromeTurkey
-
Yunyang Medical CollegeUnknown
-
BioromaUnknownOvarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome | Invitro FertilizationItaly
-
Ahmed MagedCompletedPolycystic Ovarian Syndrome
-
Mayo ClinicCompletedOverweight | Insulin Resistance | Obese | Polycystic Ovarian Syndrome (PCOS)United States
Clinical Trials on Birth control
-
Dartmouth-Hitchcock Medical CenterTerminated
-
Indiana UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingContraception | Health Care Utilization | Contraceptive UsageUnited States
-
Centre Hospitalier Universitaire de la RéunionTerminated
-
Universitaire Ziekenhuizen KU LeuvenGZA Ziekenhuizen Campus Sint-AugustinusActive, not recruiting
-
Makerere UniversityRadboud University Medical Center; University of BergenActive, not recruitingDiarrhoea | Septicaemia | Severe Illness | Lower Respiratory InfectionUganda
-
Amasya UniversityAtaturk UniversityNot yet recruitingSatisfaction, Patient | Pain, Labor
-
Ondokuz Mayıs UniversityTokat Gaziosmanpasa UniversityActive, not recruiting
-
JhpiegoBill and Melinda Gates Foundation; Addis Continental Institute of Public Health and other collaboratorsRecruitingMaternal Care PatternsEthiopia, Kenya, Nigeria
-
Aurora Health CareActive, not recruiting
-
Selcuk UniversityCompletedPain | Labor Pain | SatisfactionTurkey